The United States of America, as Represented by the Secretary, Department of Health and Human Services

Yale University

Icahn School of Medicine at Mount Sinai

The University of Texas System

Husseini K Manji

Dennis S Charney

John H Krystal

Carlos A Zarate

Sanjay J Mathew

Silvia Paddock

A John Rush

Francis J McMahon

Gonzalo E Laje

Alexander F Wilson

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (&#x3e;2 years).

Intranasal administration of ketamine to treat depression

Methods for treating suicidal ideation

The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.

Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication

The invention provides a method for determining the outcome of treatment with an antidepressant medication in a patient. In particular, the invention provides a method of screening patients to identify those patients with a decreased risk of non-response to treatment with antidepressant medication by obtaining a sample of genetic material from the patients, and then assaying the sample for the presence of a genotype which is associated with a decreased risk of non-response to treatment with antidepressant medication. The genotype is characterized by a polymorphism in the genes HTR2A, GRIK4, BCL2, and a combination thereof.

Methods to predict the outcome of treatment with antidepressant medication

Growing community of inventors

Rockville, MD, United States of America

Husseini K Manji